Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00604721 · ClinicalTrials.gov registry record · Phase 2
Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT00604721: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00604721 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00604721, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
This phase II trial is studying selumetinib to see how well it works in treating patients with locally advanced or metastatic liver cancer. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth.
Interventions
- OTHER pharmacological study
- DRUG selumetinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2007-11 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00604721
The ClinicalTrials.gov registry entry for NCT00604721 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pharmacological study is the first listed.
NCT00604721 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00604721 about?
NCT00604721 is a clinical study titled "Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer". This phase II trial is studying selumetinib to see how well it works in treating patients with locally advanced or metastatic liver cancer. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth.
What is the current status of trial NCT00604721?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2007-11. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00604721?
The interventions under investigation include: pharmacological study (OTHER), selumetinib (DRUG).
Who is sponsoring clinical trial NCT00604721?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.